Glaxosmithkline to pay up to $4.2 billion for access to Merck’s oncology division
Glaxosmithkline (GSK), the pharmaceutical giant behind some of the world’s most successful drug treatments, will pay German drugmaker Merck KGaA as much as $4.2 billion to access its potentially ground-breaking immune-oncology treatment. According to GSK, this treatment could be the catalyst in delivering “the next wave” of cancer treatments to the public. This collaboration marks the latest in a series of moves by CEO Emma Walmsley to put GSK in the market-leading position when it comes to oncology.
Glaxosmithkline’s share price has appreciated by 3% so far in 2019
Source: Yahoo Finance
Cancer treatments are the hottest property in pharmaceuticals at the moment, and companies including Roche Holdings, Novartis, Bristol-Meyers Squibb and more are expecting to see sales rise over the next few years. By 2022, oncology treatments are expected to be worth $160 billion – a 60% rise from 2017, according to Bloomberg Intelligence. Immune-oncology therapies – a type of treatment that uses the patients’ own immune system to battle tumours – is a particularly promising avenue.
GSK is hoping that the partnership will give it access to a range of cancer-killing drugs that go beyond the current wave (PD-1 inhibitors) and put it in a prime position to innovate more effective solutions. Speaking about what GSK will access as part of this deal, Axel Hoos, the company’s head of oncology research and development, said: “We need to take risks to go beyond PD-1, and we think we’re taking a pretty smart risk with this mechanism. This gives us access to a cutting-edge drug that could potentially improve on what that class is already delivering.”
Dominion holds GlaxoSmithKline in its Global Trends Managed Fund.
If you would you like to receive the Newsfeeds daily, please click here to sign up now!Help us make this Newsfeed better by rating this article. 1 star = Poor and 5 stars = Excellent
- Click here to print this story: Print
The views expressed in this article are those of the author at the date of publication and not necessarily those of Dominion Fund Management Limited. The content of this article is not intended as investment advice and will not be updated after publication. Images, video, quotations from literature and any such material which may be subject to copyright is reproduced in whole or in part in this article on the basis of Fair use as applied to news reporting and journalistic comment on events.